Myocardial infarction without ST-segment elevation (NSTEMI) is considered an inflammatory disorder associated with a high mortality rate worldwide. High-sensitivity C-reactive protein (hs-CRP) is an important inflammatory marker for NSTEMI and related to cardiovascular events. Colchicine, as a potent anti-inflammatory drug, is frequently prescribed for the treatment of gout and pericarditis. The present study aimed to evaluate the effects of colchicine, as an anti-inflammatory drug, on hs-CRP levels in NSTEMI patients. We performed a randomised, double-blind, placebo-controlled trial involving 150 NSTEMI patients referred to Imam Reza and Ghaem Hospitals affiliated to Mashhad University of Medical Sciences. The patients were randomised to receive colchicine or placebo along with optimal medications for 30 days. The hs-CRP was measured at the admission and end of the study. Our results revealed that, in both colchicine and placebo groups, hs-CRP levels were significantly mitigated in NSTEMI patients compared to baseline (P < 0.001). However, the decreasing properties of colchicine on hs-CRP levels were remarkably stronger than placebo following the 30 days of treatment (P < 0.001). Nevertheless, neither colchicine nor placebo treatment could achieve hs-CRP levels lower than 2 mg/L. There were no significant differences between the effects of colchicine on the hs-CRP decrease in diabetic and non-diabetic, male and female, and normal and preserved LVEF NSTEMI patients. It can be concluded that colchicine may prevent the disease progression and succedent cardiovascular events in NSTEMI patients by attenuating the inflammation.

无 ST 段抬高的心肌梗死 (NSTEMI) 被认为是一种与全球高死亡率相关的炎症性疾病。高敏 C 反应蛋白 (hs-CRP) 是 NSTEMI 的重要炎症标志物，与心血管事件有关。秋水仙碱作为一种有效的抗炎药，经常被用于治疗痛风和心包炎。本研究旨在评估秋水仙碱作为一种抗炎药对 NSTEMI 患者 hs-CRP 水平的影响。我们进行了一项随机、双盲、安慰剂对照试验，涉及 150 名 NSTEMI 患者，这些患者转诊至马什哈德医科大学附属的 Imam Reza 和 Ghaem 医院。患者被随机分配接受秋水仙碱或安慰剂以及最佳药物治疗 30 天。在入院和研究结束时测量 hs-CRP。我们的结果显示，在秋水仙碱组和安慰剂组中，与基线相比，NSTEMI 患者的 hs-CRP 水平显着降低。P  < 0.001)。然而，在治疗 30 天后，秋水仙碱对 hs-CRP 水平的降低作用明显强于安慰剂（P  < 0.001）。然而，秋水仙碱和安慰剂治疗都不能达到低于 2 mg/L 的 hs-CRP 水平。秋水仙碱对糖尿病和非糖尿病、男性和女性以及正常和保留 LVEF NSTEMI 患者的 hs-CRP 降低的影响没有显着差异。可以得出结论，秋水仙碱可以通过减轻炎症来预防 NSTEMI 患者的疾病进展和随后的心血管事件。